JNJ-87704916
AXP000092.1 · Oncolytic virus
- Platform
- HSV-1
- Originator
- Johnson & Johnson
- Sponsor
- Johnson & Johnson
Names
| Name | Type | Source |
|---|---|---|
| JNJ-87704916 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- conditionally replicating
- Modifications
- not disclosed
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C205181
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06311578 | A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | Recruiting | Phase 1 | 2024-04-10 | 2028-11-08 | 126 | Neoplasms |
Recent changes
No changes recorded in its trials yet.
Notes
Oncolytic HSV-1 in a phase 1 intratumoral study alone and with cetrelimab (NCT06311578, recruiting). Construct details not disclosed.
How to cite
JNJ-87704916 (AXP000092.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000092.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.